Navigation Links
NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and the University of Massachusetts Medical School announced results from a preclinical study of a Respiratory Syncytial Virus ("RSV") vaccine candidate. Novavax has licensed exclusive worldwide rights from the University of Massachusetts Medical School to certain technology for the development and commercialization of Paramyxovirus vaccines incorporating certain Virus-Like-Particles ("VLPs"). This vaccine candidate is Novavax's first recombinant VLP for the prevention of RSV disease.

The preclinical study evaluated the immunogenicity and efficacy of the RSV VLP vaccine candidate in mice. The VLP contains the matrix (i.e., "core") protein of Newcastle Disease Virus decorated with a human RSV attachment glycoprotein (Ga), which is important for inducing immunity against RSV. In this study, mice were immunized with one of four doses of the RSV VLP vaccine candidate, inactivated RSV, live RSV, or a placebo. The antibody responses to the RSV VLPs were robust and higher than the antibody responses to inactivated or live RSV. Further, antibody titers increased with higher VLP doses.

Subsets of mice that had been immunized with either RSV VLPs via intraperitoneal inoculation or live RSV via intranasal inoculation received a vaccine booster dose and were challenged with live RSV intra-nasally. Unimmunized mice were evaluated as controls. The VLP-immunized mice were protected from RSV replication in the lungs. Further, the lung tissue of these mice showed no evidence of enhanced inflammation after RSV challenge/infection, which has been reported with a formalin-inactivated RSV vaccine.

In summary, the candidate VLP vaccine induced strong antibody responses against RSV, protected mice against RSV replication in the lungs, and did not lead to enhanced inflammation of the airways. These data support continued development of this and additional RSV VLP vaccine candidates containing other proteins (i.e., Gb and F) important for immunity.

"I am pleased we have been able to demonstrate that virus-like particles, based on Newcastle disease virus proteins, can be used as a platform for the development of human vaccines," said Trudy G. Morrison, PhD, professor of molecular genetics & microbiology, who presented the results of the study, supported by Novavax, at the 2nd Vaccine Congress in Boston today.

"Consistent with the strategy to expand our vaccine pipeline, this new program has the potential to address a significant unmet medical need in both infants and elderly patients over 65 years of age," said Dr. Rahul Singhvi, Novavax's President and CEO. "The initial preclinical results from this first RSV vaccine candidate in partnership with the University of Massachusetts Medical School further demonstrate the potential of our proprietary vaccine and manufacturing technologies and represent an important opportunity to enhance shareholder value."

About Respiratory Syncytial Virus

RSV is the most commonly identified cause of lower respiratory tract infection in infants and young children with repeated infections causing moderate to severe cold-like symptoms throughout life. High risk individuals (including the elderly over age 65 years, people with cardiovascular disease and children less than four years of age) may also develop lower respiratory tract infections leading to bronchiolitis and pneumonia. It is estimated that more than 8.5 million adults, including the elderly over age 65 years, are infected and 900,000 patients are hospitalized annually due to RSV infection in the US and major European countries. In the United States alone there are 177,500 hospitalizations in high risk adults including the elderly over age 65, resulting in annual medical costs exceeding $1 billion. In addition, there are up to 125,000 infants in the US who are hospitalized annually due to RSV. There is currently no approved vaccine for the prevention of RSV; the market potential for such a vaccine would be well in excess of $1 billion annually.

About UMass Medical School

The University of Massachusetts Medical School is one of the fastest growing academic health centers in the country and has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $193 million in extramural research funding annually. Research dollars enable UMMS scientists to explore human disease from the molecular level to large-scale clinical trials. Basic and clinical research has led to new approaches for diagnosis, treatment and prevention of disease. Visit for additional information.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before FDA can be applied for and the FDA may not approve the pandemic vaccine even if further trial results are similar to those disclosed herein; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
2. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
3. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
4. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
5. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
6. Novavax CEO to Present at BIO Investor Forum 2008
7. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
8. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
9. Novavax Announces Closing of $18 Million Registered Direct Offering
10. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
11. Novavax to Join Russell 3000 Index
Post Your Comments:
(Date:10/8/2015)... 2015  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... within its Applied Diagnostics and Testing business segment ... product line with ten certified Snap-N-Spike ® ... and their stable-labeled internal standards. These new solution ... taurocholic acid and native and deuterium-labeled analogs of ...
(Date:10/7/2015)... India , October 8, 2015 /PRNewswire/ ... --> Medical biotechnology accounts for largest ... of bioinformatics in drug discovery and development ... . ... On the basis of applications, the ...
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. (OTCQX: ... nutritional ingredients that creates science-based solutions for dietary ... and pharmaceutical products, today announced that the October ... and Founder, is now available for on-demand viewing ... -->   --> ...
(Date:10/7/2015)... RADNOR, Pa. , Oct. 7, 2015   ... global, independent provider of laboratory products, services and ... Technologies Inc. (PTI), a specialty solvent company that ... solvents. This acquisition will enhance VWR,s growing laboratory ... its laboratory and biopharmaceutical manufacturing customers. ...
Breaking Biology Technology:
... Future of Work World Congress , an energizing two-day ... development came together to envision the future workplace and develop ... Hill district and Independence Mall area of Philadelphia where the ... the restored and the new. This part of the city ...
... , a privately held IT firm, said it has acquired ... ,Berbee said it expects to keep all 16 employees of ... all. Strategies & Solutions provides hardware, software and services built ... ,Berbee has regional offices throughout the Midwest region, some of ...
... made a new version of its Mediasite presentation recorder for ... units to date and hopes to create a bigger market. ... show such as a PowerPoint deck with a video of ... a webcast. , ,According to company statements the Japanese market ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/26/2015)... 26th, 2015  Results of a TactioRPM pilot ... today at the Stanford Medicine X Conference. In ... Dashboards, Connected Health Devices and Pharmacogenomics", Roger ... will explain how senior patients equipped with connected ... pharmacist via the TactioRPM remote patient monitoring platform ...
Breaking Biology News(10 mins):
... New findings by Virginie Stevens ( CNRS ), Jean ... ) and colleagues show that interactions between dispersal and ... was published as open access paper in the journal ... plays a key role in gene flow among populations, ...
... decision making mechanisms in the human brain could mirror how ... have been found in decision making systems between humans and ... could teach us about how our brains work. Experts ... often paralysing thought process in humans, with scouts who seek ...
... solved the three-dimensional structure of a key region ... that control the activity of genes associated with ... understand the molecular mechanisms that regulate bacterial pathogenicity ... to conventional antibiotics. According to Jess Garca, research ...
Cached Biology News:
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: